Personally for me, it complicates things and leads to a lot of quesitons.

If this patent application is approved, and Pfizer gets ownership of BET inibitors (including apabetalone) as a method of increasing frataxin...What is the impact?  If someone suffering from CKD takes apabetalone...the drug has the ancilliary effect of increasing frataxin in that individual I would assume.  

The fact that Zenith is working with Zenith, but not with Resverlogix....more questions.  The waters are very murky here for me.  I don't have any answers, just questions.